Move to topTop
Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of primary container, injection and infusion therapy devices, has launched a ready-to-fill polymer syringe for challenging biotech drugs with larger volume.

The PLAJEX™ 2.25 mL with Tapered Needle* is specifically designed to meet the Biotech market, making it suitable for complex drug applications, such as high viscosity biotech medications.

The syringe enables pharmaceutical customers to offer a safe, easy-to-use, and effective treatment option that maximizes patient convenience.

Yuki Takeuchi, Global Product Manager for PLAJEX™ platform, said that the syringes are designed to address the unmet needs of biotech companies that are dealing with challenging and highly viscous biologic drugs, such as highly concentrated monoclonal antibodies.

He said: "With the rise of biologic formulations, and the increasing trend in self-administration, a drug delivery device needs to be easy-to-use, be able to deliver drugs safely, comfortably with suitable force. Our latest offering with Tapered Needle technology addresses the challenge of delivering highly viscous drugs without compromising patient comfort." 

"Some biologic drugs are less stable in a liquid formulation, therefore PLAJEX™ syringe is designed as silicone oil-free which contributes to keeping sensitive drugs stable." 

As the latest addition to the PLAJEX™ range, these primary container solutions come sterilized, and ready for filling, offering silicone oil-free, tungsten-free and glue-free containers made with precise polymer molding technology to provide tight dimensional tolerances.

Terumo's proprietary i-coating™ stopper technology eliminates the need of silicone oil in the syringe system while providing consistent and predictable break-loose and glide forces. 

The PLAJEX 2.25 mL with Tapered Needle is compatible with some of marketed injection devices, while additional compatibility studies are ongoing with leading device providers.

Terumo Pharmaceutical Solutions will help customer's smooth fill & finish integration either by offering Terumo's in-house CDMO (Contract Development and Manufacturing Organization) capability, or supporting drug filling sites selected by customer. 

Anil Busimi, VP Strategy & Marketing, added: "Terumo is in a unique position being able to offer an integrated solution of primary container and fill & finish capability. We continue to expand our portfolio with innovative injectable drug delivery solutions to meet pharma customers and patient's needs."
* Tapered Needle: A conically shaped needle enabled by Terumo's proprietary needle cannula manufacturing technology to improve injectability while keeping a small needle size at the point of patient contact.


About Terumo Pharmaceutical Solutions 

Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety. Globally trusted for quality and precision, Terumo offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services as well as a portfolio of injection, infusion, and primary packaging solutions. Terumo Pharmaceutical Solutions has decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to the latest stages of product commercialization to optimize critical aspects of parenteral drug delivery. Our comprehensive parenteral delivery product portfolio of injection, infusion, and primary packaging solutions offers innovative drug delivery technologies ready for today's most demanding applications.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.